Boehringer's Dual-Hormone Peptide Hit Two Targets in a Diabetes Trial

In a 755-person trial published today in The New England Journal of Medicine, an experimental peptide that deliberately activates a hormone receptor best known for raising blood sugar pushed nearly three in ten participants with type 2 diabetes into a normal blood-sugar range, while cutting their body weight by an average of 13.1%.

The peptide is survodutide, developed by Boehringer Ingelheim under license from Zealand Pharma. The results, from the Phase 3 trial SYNCHRONIZE-2, were published the same day they were presented at the European Association for the Study of Diabetes' 2026 meeting, according to Boehringer Ingelheim's announcement and Zealand Pharma's own release.

Inside the SYNCHRONIZE-2 trial

The double-blind, placebo-controlled trial randomly assigned 755 adults with obesity or overweight and type 2 diabetes to once-weekly injections of survodutide, at one of two doses (3.6 or 6.0 milligrams), or to placebo, for 76 weeks, according to the companies' releases and independent coverage from AJMC and PharmaShots.

At the higher dose, participants lost up to 13.1% of their body weight on average, compared with 3.1% on placebo, and 79.3% reached at least 5% weight loss versus 32.7% on placebo. Blood sugar control improved alongside the weight loss: average HbA1c (a measure of blood sugar over roughly three months) fell by 1.21 percentage points from a baseline of 7.4%, versus a 0.03-point drop on placebo, and 29.5% of participants reverted to a normal HbA1c range entirely, compared with 4.0% on placebo. Waist circumference fell by 11.1 centimeters on average, versus 3.5 centimeters on placebo.

On tolerability, the most common side effects were gastrointestinal — nausea, vomiting, diarrhea and constipation, mostly described as mild to moderate. Still, 18% of participants on survodutide stopped the drug over a gastrointestinal adverse event, compared with 1.2% on placebo; the companies' releases note most of those discontinuations happened during the early dose-escalation period, and that newer trials in the same program now use more gradual titration schedules.

Lead investigator Sean Wharton said the glycemic results matter beyond the scale: "Seeing improvements in glycemic control and insulin sensitivity alongside weight loss provides evidence that tackling obesity can positively influence broader metabolic health." Zealand Pharma's chief medical officer, David Kendall, said the results "demonstrate the potential of survodutide in people living with obesity and type 2 diabetes, by providing both meaningful weight loss and glycemic control."

Why pair a sugar-raising hormone with a diabetes drug

Survodutide is what researchers call a dual agonist: it activates both the GLP-1 receptor and the glucagon receptor. The GLP-1 pathway is familiar from the current wave of obesity and diabetes drugs — it slows digestion, promotes a feeling of fullness and prompts the pancreas to release more insulin when blood sugar is high. It's the same receptor targeted by Novo Nordisk's semaglutide and, alongside a second receptor, by Eli Lilly's tirzepatide.

Glucagon has a well-earned reputation as the hormone that raises blood sugar; pairing it with a diabetes drug sounds, on paper, like fighting fire with fire. But glucagon receptor activity does more than release stored sugar from the liver — it also appears to increase energy expenditure and promote the breakdown of liver fat. Researchers developing this class of drugs have proposed that adding glucagon-receptor activity to a GLP-1 drug recruits that fat-burning and liver-fat-reducing effect to reinforce weight loss, while the GLP-1 side of the molecule offsets glucagon's usual tendency to push blood sugar up. A broader primer on how incretin-pathway peptides work in general is available on Torrey Labs' independent compound guide, /learn.

What the trial does, and doesn't, show

SYNCHRONIZE-2 is a completed Phase 3 trial that met its co-primary endpoints, which puts survodutide further along than most peptides covered on this journal. Boehringer Ingelheim already holds several regulatory designations meant to speed its review, including an FDA Fast Track designation from 2021 and an FDA Breakthrough Therapy designation from September 2024 for a liver condition, metabolic dysfunction-associated steatohepatitis, according to the Zealand Pharma release.

But several questions remain open. The trial compared survodutide against placebo, not against an existing GLP-1 or dual-agonist drug, so it doesn't show whether survodutide's combination of benefits would hold up, or look different, in a head-to-head comparison. It also didn't include an arm isolating the glucagon-receptor component on its own, so it can't by itself prove how much of the result comes from adding that pathway rather than from a particularly strong GLP-1 effect alone. A companion trial in people with obesity who don't have diabetes, SYNCHRONIZE-1, and a dedicated cardiovascular outcomes trial, SYNCHRONIZE-CVOT, are both still to be reported — the cardiovascular results are expected later this year, according to the companies. The trial was sponsored by Boehringer Ingelheim, survodutide's developer, which is standard for a drug trial at this stage but worth noting plainly.

What this means for researchers

Taken on its own, SYNCHRONIZE-2 is evidence that a dual-receptor peptide can improve both weight and glycemic measures in people who have type 2 diabetes alongside obesity, without the tolerability data looking obviously worse than single-pathway GLP-1 drugs. It's the second diabetes-focused peptide trial result to land on this journal within the last week — Roche's enicepatide pushed 62% of a 447-person trial group to a normal blood-sugar range in late September, compared with survodutide's 29.5% — a reminder that these trials differ in population, dose, duration and endpoint definitions, so the headline percentages aren't directly comparable to each other even when they sound similar.

What would resolve the open questions is more trial data, not more trial coverage: a head-to-head study against an approved GLP-1 or dual-agonist drug, a report from the ongoing cardiovascular outcomes trial, and longer follow-up past 76 weeks to see whether the weight and glycemic effects are maintained. Until those exist, SYNCHRONIZE-2 should be read as one well-designed trial showing a specific drug worked for a specific population over a specific period — a meaningful data point in a crowded field, not a verdict on it.